Southern Star Research News and Resources

FibroBiologics, Inc. has completed onboarding clinical sites for its Phase 1/2 clinical trial evaluating CYWC628, an investigational therapy for the treatment of refractory diabetic foot ulcers (DFUs). The prospective, multicenter, open-label study will assess the safety, tolerability, and efficacy of

Halia Therapeutics, Inc. has entered a strategic collaboration with Southern Star Research Pty Ltd, an Australian contract research organisation (CRO), to launch a Phase 1 clinical trial for its LRRK2 inhibitor, HT-4253. This collaboration signifies a crucial step in the